App Pharmaceuticals, Inc. - Current report filing (8-K)
05 September 2008 - 6:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT
OF 1934
Date of report (Date of earliest event reported): September 5, 2008
APP PHARMACEUTICALS, INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
0-33407
|
|
30-0431736
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
1501 East Woodfield Road, Suite 300 East, Schaumburg, IL
|
|
60173
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (847) 969-2700
N/A
(Former Name or Former Address,
if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
APP Pharmaceuticals, Inc., a Delaware
corporation (APP), is mailing to its stockholders a supplement, dated as of September 5, 2008, to the information statement/prospectus previously mailed to APPs stockholders in connection with the contemplated acquisition of
APP by Fresenius SE (such supplement, the information statement/prospectus supplement). The information statement/prospectus supplement is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
ITEM 9.01
|
Financial Statements and Exhibits.
|
23.1 Consent of Lazard Frères & Co.
23.2 Consent of Goldman, Sachs & Co.
99.1 Information
Statement/Prospectus Supplement, Dated September 5, 2008
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
APP PHARMACEUTICALS, INC.
(REGISTRANT)
|
|
|
By:
|
|
/
S
/ R
ICHARD
M
AROUN
|
|
|
Richard Maroun
Chief Administrative Officer
and General Counsel
|
Dated: September 5, 2008
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
23.1
|
|
Consent of Lazard Frères & Co.
|
|
|
23.2
|
|
Consent of Goldman, Sachs & Co.
|
|
|
99.1
|
|
Information Statement/Prospectus Supplement, Dated September 5, 2008
|
App Pharmaceuticals (MM) (NASDAQ:APPX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
App Pharmaceuticals (MM) (NASDAQ:APPX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
Echtzeit-Nachrichten über App Pharmaceuticals (MM) (NASDAQ): 0 Nachrichtenartikel
Weitere App Pharmaceuticals, Inc. News-Artikel